Is there benefit in dual renin– angiotensin–aldosterone system blockade? No, yes and maybe: A guide for the perplexed

Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease

(2013) Regina Kunz et al.   ANNALS OF INTERNAL MEDICINE

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE

(2012) John J.V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

2009 Canadian Hypertension Education Program recommendations: The scientific summary – an annual update

(2011) Norman R.C. Campbell et al.   CANADIAN JOURNAL OF CARDIOLOGY

Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction

(2011) Scott D. Solomon et al.   EUROPEAN HEART JOURNAL

Beyond ONTARGET: angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in combination, a lesser evil in some?

(2010) J. Wong et al.   DIABETES OBESITY & METABOLISM

Of fads, fashion, surrogate endpoints and dual RAS blockade

(2010) F. H. Messerli et al.   EUROPEAN HEART JOURNAL

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOS

(2010) Henry Krum et al.   EUROPEAN JOURNAL OF HEART FAILURE

Have we fallen off target with concerns surrounding dual RAAS blockade?

(2010) Michael R. Lattanzio et al.   KIDNEY INTERNATIONAL

Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D)

(2009) L. F. Fried et al.   Clinical Journal of the American Society of Nephrology

Aldosterone-receptor antagonism in hypertension

(2009) Pieter M Jansen et al.   JOURNAL OF HYPERTENSION

The Sudden Demise of Dual Renin-Angiotensin System Blockade or the Soft Science of the Surrogate End Point

(2009) Franz H. Messerli   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Retraction—Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

(2009) The Editors of The Lancet   LANCET

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

(2009) H.-H. Parving et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes

(2009) Michael Mauer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study

(2008) Steven A. Yarows et al.   ADVANCES IN THERAPY

Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review

(2008) Andrew S. Bomback et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)

(2008) et al.   EUROPEAN HEART JOURNAL

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

(2008) Nish Chaturvedi et al.   LANCET

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

(2008) Johannes FE Mann et al.   LANCET

Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy

(2008) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Aliskiren and Dual Therapy in Type 2 Diabetes Mellitus

(2008) Julie R. Ingelfinger   NEW ENGLAND JOURNAL OF MEDICINE